Racial or ethnic differences in allele frequencies of sinqle-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 65, Issue 9, 2006, Pages 1213-1218

  Hughes, L B ^a   Beasley, T M ^a   Patel, H ^a   Tiwari, H K ^a   Morgan, S L ^a   Baggott, J E ^a   Saag, K G ^a   McNicholl, J ^b   Moreland, L W ^a   Alarcon G S ^a   Bridges Jr , S L ^a  

^a The University of Alabama at Birmingham   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); METHOTREXATE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALOPECIA; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; CHILL; CONCENTRATION LOSS; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DRUG EFFICACY; DYSPEPSIA; DYSPNEA; EAR DISEASE; ETHNIC DIFFERENCE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; INSOMNIA; LEUKOPENIA; LIBIDO DISORDER; LUNG DISEASE; MAJOR CLINICAL STUDY; NAUSEA; NEUROPATHY; NOSE DISEASE; PANCREATITIS; PETECHIA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISEASE; SOMNOLENCE; STOMATITIS; SWEATING; THROAT DISEASE; THROMBOCYTOPENIA; TINNITUS; VERTIGO; VESICULAR RASH; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

AFRICAN AMERICANS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; HAPLOTYPES; HUMANS; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33747805632     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.046797     Document Type: Article

References (40)

1. Alarcon GS. Methotrexate use in rheumatoid arthritis. A clinician's perspective. Immunopharmacology 2000;47:259-71.
2. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001;134:695-706.
3. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266-73.
4. Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998;101:295-300.
5. Goyette P, Pai A, Milos R, Frosst P, Tran P, Chen Z, et al. Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mamm Genome 1998;9:652-6.
6. Schubert HL, Blumenthal RM, Cheng X. Many paths to methyltransfer: a chronicle of convergence. Trends Biochem Sci 2003;28:329-35.
7. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003;146:948-57.
8. Gos M Jr, Szpecht-Potocka A. Genetic basis of neural tube defects. II. Genes correlated with folate and methionine metabolism. J Appl Genet 2002;43:511-24.
9. Schwahn B, Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenomics 2001;1:189-201.
10. Bailey LB. Folate, methyl-related nutrients, alcohol, and the MTHFR 677C→T polymorphism affect cancer risk: intake recommendations. J Nutr 2003;133(Suppl 1):3748-53S.
11. Stegmann K, Ziegler A, Ngo ET, Kohlschmidt N, Schroter B, Ermert A, et al. Linkage disequilibrium of MTHFR genotypes 677C/T-1298A/C in the German population and association studies in probands with neural tube defects(NTD). Am J Med Genet 1999;87:23-9.
12. Rosenberg N, Murata M, Ikeda Y, Opare-Sem O, Zivelin A, Geffen E, et al. The frequent 5,10-methylenetetrahydrofolate reductase C677T polymorphism is associated with a common haplotype in whites, Japanese, and Africans. Am J Hum Genet 2002;70:758-62.
13. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998;62:1044-51.
14. van Ede AE, Loan RF, Blom HJ, Huizinga TW, Haagsma CJ, Giesendorf BA, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001;44:2525-30.
15. Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmocogenetics 2002;12:183-90.
16. Berkun Y, Levartovsky D, Rubinow A, Orbach H, Aamar S, Grenader T, et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the Al 298C polymorphism of the MTHFR gene. Ann Rheum Dis 2004;63:1227-31.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
18. Bridges SL Jr, Jenq G, Moran M, Kuffner T, Whitworth WC, McNicholl J. Single-nucleotide polymorphisms in tumor necrosis factor receptor genes: definition of novel haplotypes and racial/ethnic differences. Arthritis Rheum 2002;46:2045-50.
19. Saag KG, Kolluri S, Koehnke RK, Georgou TA, Rachow JW, Hunninghake GW, et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum 1996;39:1711-19.
20. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med 1994;121:833-41.
21. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New Engl J Med 2000;343:1586-93.
22. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
23. Prevoo ML, 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eiqht-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
24. Sell SM, Lugemwa PR. Development of a highly accurate, rapid PCR-RFLP genotyping assay for the methylenetetrahydrofolate reductase gene. Genet Testing 1999;3:287-9.
25. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
26. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12:921-7.
27. Slatkin M, Excoffier L. Testing for linkage disequilibrium in genotypic data using the Expectation-Maximization algorithm. Heredity 1996;76(Pt 4):377-83.
28. Ranganathan P, Culverhouse R, Marsh S, Ahluwalia R, Shannon WD, Eisen S, et al. Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. Pharmacogenomics 2004;5:559-69.
29. Parra EJ, Marcini A, Akey J, Martinson J, Batzer MA, Cooper R, et al. Estimating African American admixture proportions by use of population-specific alleles. Am J Hum Genet 1998;63:1839-51.
30. Khanna D, Park GS, Paulus HE, Simpson KM, Elashoff D, Cohen SB, et al. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Arthritis Rheum 2005;52:3030-8.
31. Bridges SL Jr, Hughes LB, Mikuls TR, Howard G, Tiwari HK, Alarcon GS, et al. Early rheumatoid arthritis in African-Americans: the CLEAR registry. Clin Exp Rheumatol 2003;21(Suppl 31):S138-45.
32. Leclerc D, Odievre M, Wu Q, Wilson A, Huizenga JJ, Rozen R, et al. Molecular cloning, expression and physical mapping of the human methionine synthase reductase gene. Gene 1999;240:75-88.
33. Hobbs CA, Sherman SL, Yi P, Hopkins SE, Torfs CP, Hine RJ, et al. Polymorphisms in genes involved in folate metabolism as maternal risk factors for down syndrome. Am J Hum Genet 2000;67:623-30.
34. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-82.
35. Singer MJ, Mesner LD, Friedman CL, Trask BJ, Hamlin JL. Amplification of the human dihydrofolate reductase gene via double minutes is initiated by chromosome breaks. Proc Natl Acad Sci USA 2000;97:7921-6.
36. Rayl EA, Moroson BA, Beardsley GP. The human purH gene product, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase. Cloning, sequencing, expression, purification, kinetic analysis, and domain mapping. J Biol Chem 1996;271:2225-33.
37. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004;50:2766-74.
38. Terao M, Kurosaki M, Demontis S, Zanotta S, Garattini E. Isolation and characterization of the human aldehyde oxidase gene: conservation of intron/exon boundaries with the xanthine oxidoreductase gene indicates a common origin. Biochem J 1998;332(Pt 2):383-93.
39. Baggott JE, Bridges SL Jr, Morgan SL. Evidence for two phenotypes in the metabolism of methotrexate to 7-hydroxymethotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2005;52:356-8.
40. Kager L, Cheok M, Yang W, Zaza G, Cheng Q, Panetta JC, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 2005;115:110-17.